Novo Nordisk's Semaglutide Improves Liver Health in Non-Obese MASH Patients in Trial Analysis

By Public Technologies
  • Novo Nordisk will present new liver research on Wegovy and investigational efruxifermin at The Liver Meeting, November 5-9, 2026, in Denver.
  • A post-hoc analysis of the phase 3 ESSENCE trial found semaglutide improved liver health in non-obese participants with MASH.
  • Analyses from the phase 2b SYMMETRY trial showed efruxifermin improved liver scarring in participants with MASH cirrhosis, including those with cardiometabolic conditions.
  • The PLATINUM-Truveta retrospective study will present comparisons of semaglutide and resmetirom on liver enzymes and cardiometabolic markers in routine clinical practice.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk